Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

155.10 -1.69 (-1.08%)
Streaming Delayed Price Updated: 1:25 PM EDT, Aug 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
58 59 Next >
News headline image
Johnson & Johnson's Carvykti Stands Ahead Of Bristol Myers' Rival Blood Cancer Therapy With FDA Approval For Wider Population ↗
FDA approves Johnson & Johnson's Carvykti, a BCMA-targeted therapy for relapsed or refractory multiple myeloma patients, offering hope with increased manufacturing capacity and extended collaboration... 
Via Benzinga
News headline image
Why Is Novartis Stock Trading Higher On Thursday? ↗
Novartis to file Pluvicto pre-taxane label expansion in 2H 2024 based on Phase 3 PSMAfore study data. Updated overall survival results show HR<1.0 in ITT population. rPFS consistent. Safety profile... 
Via Benzinga
Novartis AG (NYSE: NVS) Highlighted for Surprising Price Action
Via Investor Brand Network
News headline image
Harnessing AI for Drug Discovery: Top 3 Stocks to Watch ↗
As biotech innovators look to AI to smoothen out the drug discovery process, the leaders in the scene could stand to benefit greatly. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
Magnificent 7 Stocks Become The Star Attractions For Norway's Sovereign Wealth Fund ↗
Norway's sovereign wealth fund has just five equity investments that represent nearly 13% of its total equity allocation. 
Via Benzinga
News headline image
1 Magnificent Dividend Stock to Buy and Hold ↗
The company's business went through some important changes last year. 
Via The Motley Fool
News headline image
2 Dividend Stocks to Buy and Hold Forever ↗
These businesses look too strong to fail. 
Via The Motley Fool
5 Tips to Manage Heart Health After a Heart Attack
(BPT) - By Dr. Norman Lepor 
Via Brandpoint
News headline image
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities ↗
Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Meanwhile, Novo Nordisk announced plans to invest $556 million to expand its Tianjin city production facility. 
Via Talk Markets
News headline image
Ozempic Users Speak Out Over Side Effects, Lawsuits Against Novo Nordisk And Eli Lilly Surge ↗
Legal actions surge against diabetes drug manufacturers Eli Lilly and Novo Nordisk. Patients allege severe complications, including gallbladder issues and gastroparesis, tied to GLP-1 agonists. Over 60... 
Via Benzinga
Topics Lawsuit
News headline image
GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy ↗
Key Takeaways: GenScript’s cell therapy revenue grew by 143.7% last year as a CAR-T cell therapy developed by its Legend Biotech subsidiary gained traction Legend’s Carvykti is expected to hit annual... 
Via Benzinga
News headline image
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform ↗
Unlock potential with Voyager Therapeutics as HC Wainwright initiates coverage highlights its TRACER capsid platform, promising CNS-targeted gene therapies and strategic partnerships driving long-term... 
Via Benzinga
News headline image
Looking Into Novartis's Recent Short Interest ↗
 
Via Benzinga
News headline image
FDA Approves BeiGene's First Drug Candidate Produced Through Its Immuno-Oncology Program For Esophageal Cancer ↗
FDA approves BeiGene's Tevimbra for esophageal squamous cell carcinoma, offering hope for patients after prior chemotherapy. Tevimbra's efficacy was demonstrated in the RATIONALE 302 trial with... 
Via Benzinga
Biotech’s Role in Addressing the Pancreatic Cancer Emergency
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVX),(NASDAQ:IBRX),(NASDAQ:ACRS),(NYSE:NUVB) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Top Wall Street Analysts Flag US Market Concentration Anxiety, Advise Investors To Adopt 'Barbell Approach' ↗
Goldman Sachs urges investors to diversify geographically due to high concentration in US tech stocks, with Japan, healthcare, and European GRANOLAS highlighted as promising markets. 
Via Benzinga
News headline image
3 Dividend Stocks to Buy Hand Over Fist in March ↗
Income investors might want to load up on these great dividend stocks. 
Via The Motley Fool
News headline image
FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer ↗
FDA grants accelerated approval to BeiGene's Brukinsa for relapsed/refractory follicular lymphoma. Approved in combination with Roche's Gazyva after two or more lines of therapy. Brukinsa, priced at... 
Via Benzinga
News headline image
Medicare's Ambitious Drug Price Negotiation Plan: President Joe Biden Calls To Expand Targeted Medicines To 50 Annually by 2029 ↗
Explore President Biden's plan to expand Medicare drug negotiations, targeting at least 50 drugs annually. Uncover the impact on pharmaceutical profits and the broader health-care policy proposals,... 
Via Benzinga
News headline image
Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, Toddlers ↗
Biogen's latest SMA research! Interim data from the RESPOND study reveals promising outcomes with SPINRAZA treatment. Learn about reduced NfL levels and the impact on infants and children with spinal... 
Via Benzinga
News headline image
Biden's State Of The Union: Grading His Results On Abortion Access, Drug Prices And Opium Epidemic ↗
As President Biden prepares for his State of the Union address, he will address issues such as Bidenomics, healthcare, and the US's role in the world. 
Via Benzinga
News headline image
Novartis Reveals Promising Gene Therapy Data for Treating Spinal Muscular Atrophy in Older Children ↗
Novartis' Zolgensma gene therapy for spinal muscular atrophy latest SMART Phase 3b study reveals safety, efficacy, and significant milestones achieved. $1.21 billion sales reported in FY2023. 
Via Benzinga
News headline image
3 Stocks Primed for Exponential Returns by 2034 ↗
As investors, It's always good to look at things long-term. Here are three stocks that are primed for exponential returns in ten years. 
Via InvestorPlace
News headline image
11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields ↗
A group of stocks, which Goldman Sachs dubbed the "Granolas," accounted for 50% of gains of the Stoxx Europe 600 Index for the past year. 
Via Benzinga
News headline image
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining... 
Via Newsfile
News headline image
Celldex Stock Hits 11-Month High, Up 19%, On A Promising New Hives Treatment ↗
The company tested its treatment in chronic spontaneous urticaria. Almost 38% of patients had "complete control" after 12 weeks. 
Via Investor's Business Daily
News headline image
This Drug By Roche And Novartis Reduces Allergic Reactions Across Multiple Foods For People With Food Allergies ↗
Results from Roche's Phase 3 OUtMATCH study on Xolair for multi-food allergies. Published in NEJM, the study reveals increased tolerance in patients aged 1-55. FDA-approved expanded use for... 
Via Benzinga
News headline image
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential ↗
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months. 
Via Talk Markets
News headline image
Move Over Magnificent 7, Say Hello to the GRANOLAS ↗
Dive into the compelling world of GRANOLAS stocks: Europe's elite players shaping the future of pharmaceuticals, tech, and consumer goods. 
Via InvestorPlace
News headline image
Exit Now! 3 Biotech Stocks to Sell in February 2024 ↗
These biotech stocks to sell represent incredibly risky bets, amidst the sector's volatility and looming economic unpredictability. 
Via InvestorPlace
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
58 59 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.